Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies. [PDF]
Anatriello A +6 more
europepmc +1 more source
Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Clinical evidence and insights. [PDF]
Maideen NMP +3 more
europepmc +1 more source
Emerging risk of non-arteritic anterior ischemic optic neuropathy (NAION) with semaglutide: a safety alert for clinicians. [PDF]
Safi MQ, Hussain MD, Chaity NJ.
europepmc +1 more source
Anti-obesity medications impacting the eye: An emerging concern - a narrative review. [PDF]
Khullar S +5 more
europepmc +1 more source
Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations. [PDF]
Wu TE, Chen HS.
europepmc +1 more source
The Effects of GLP-1 Receptor Agonists on Retinal Microvascular Alterations. [PDF]
Lampsas S +8 more
europepmc +1 more source
Potential Value of Novel Lipid-Derived Indicator as a Biomarker for Nonarteritic Anterior Ischemic Optic Neuropathy. [PDF]
Cong C +5 more
europepmc +1 more source
Blamed but not at fault: anti-obesity medication adverse effects misidentified as perioperative complications - a comprehensive review and medicolegal warning for anesthesiologists. [PDF]
Kwak HJ, Choi JJ, Lee D, Jo YY.
europepmc +1 more source
HbA1c kinetics as a prognostic marker of ophthalmic risk in GLP-1 receptor agonist therapy. [PDF]
Margoni A +2 more
europepmc +1 more source
40 Hz flicker preconditioning protects nonarteritic anterior ischemic optic neuropathy via adenosine signaling. [PDF]
Su L +12 more
europepmc +1 more source

